adezunap (AP707) / CannaXan, Apurano Pharma - LARVOL DELTA

Illuminate: Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder (clinicaltrialsregister.eu) - P1/2 | N=154 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P1/2 trial • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder

Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Back Pain • Musculoskeletal Pain • Pain

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Back Pain • Musculoskeletal Pain • Pain

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Central Neuropathic Pain • CNS Disorders • Multiple Sclerosis • Musculoskeletal Pain • Neuralgia • Pain • Vascular Neurology

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Central Neuropathic Pain • CNS Disorders • Multiple Sclerosis • Musculoskeletal Pain • Neuralgia • Pain • Vascular Neurology

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - P3 | N=558 | Recruiting | Sponsor: Apurano Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting

Enrollment open • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Back Pain • Musculoskeletal Pain • Pain

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Back Pain • Musculoskeletal Pain • Pain

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Cardiovascular • Central Neuropathic Pain • CNS Disorders • Multiple Sclerosis • Musculoskeletal Pain • Neuralgia • Pain • Vascular Neurology

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - P3 | N=558 | Not yet recruiting | Sponsor: Apurano Pharmaceuticals GmbH

New P3 trial • Cardiovascular • Central Neuropathic Pain • CNS Disorders • Multiple Sclerosis • Musculoskeletal Pain • Neuralgia • Pain • Vascular Neurology